Clinical Trials Logo

Pancreatic Adenocarcinoma clinical trials

View clinical trials related to Pancreatic Adenocarcinoma.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06157671 Enrolling by invitation - Clinical trials for Pancreatic Adenocarcinoma

The LINFU® U.S. Registry for the Detection of Asymptomatic Pancreatic Ductal Adenocarcinoma

Start date: January 31, 2024
Phase:
Study type: Observational

Adenocyte has developed LINFU®, (Low Intensity Non-Focused Ultrasound excitation of the pancreas) as a method of identifying early, asymptomatic pancreatic cancer and its noninvasive precancerous lesions. The test involves ultrasound and an analysis of pancreatic juice. A neural network-based computer-assisted system may be utilized to enhance the analysis. Patients enrolled are being screened for pancreatic cancer because they have known risk factors (i.e. smoking, diabetes, chronic pancreatitis, family history of pancreatic cancer, or certain genetic syndromes).

NCT ID: NCT06102889 Enrolling by invitation - Clinical trials for Pancreatic Adenocarcinoma

GUIDING MULTI-MODAL THERAPIES AGAINST MINIMAL RESIDUAL DISEASE BY LIQUID BIOPSIES

GUIDEMRD
Start date: May 2, 2024
Phase:
Study type: Observational

The overall objective of this study is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice. Primary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence. Specifically, we want to determine the association between disease-free survival (DFS) and ctDNA detection status after (1) curative-intended surgery and (2) adjuvant chemotherapy.